Form 4: Director Keith G. Myers Receives Sanara MedTech Equity Grant

Director Keith G. Myers was granted 4,385 shares of restricted stock in Sanara MedTech Inc. as part of the 2024 Omnibus Long-Term Incentive Plan.

Summary

• Director Keith G. Myers acquired 4,385 shares of common stock in Sanara MedTech Inc. (SMTI).
• The shares were granted as restricted stock under the company's 2024 Omnibus Long-Term Incentive Plan.
• The transaction occurred on June 4, 2026, at a price of $0 per share, representing an equity-based compensation grant.
• Following this transaction, the reporting person's total direct beneficial ownership increased to 9,325 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Retention of key leadership personnel via the 2024 Omnibus Long-Term Incentive Plan.

Negatives

• The issuance of restricted stock results in minor dilution to existing shareholders.

Risks

• Vesting is contingent upon the director providing continued services to the issuer through the vesting date.

Future Outlook

The restricted stock is scheduled to vest on the earlier of the 2027 annual shareholder meeting or June 4, 2027, subject to continued service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices designed to incentivize long-term strategic oversight and align board interests with shareholder outcomes in the medical technology sector.

Comparison to Industry Standards

• The use of an Omnibus Long-Term Incentive Plan is consistent with standard compensation practices for small-to-mid-cap medical technology companies.
• Granting restricted stock with a one-year cliff or annual meeting-based vesting schedule is a common retention mechanism for board members.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor dilution impact.
• Director: Increased equity stake in the company.

Next Steps

• Vesting of the 4,385 restricted shares on or before June 4, 2027.

Key Dates

Keywords

Sanara MedTech, SMTI, Form 4, Insider Trading, Equity Compensation, Director Compensation